Cargando…

Amrubicin: potential in combination with cisplatin or carboplatin to treat small-cell lung cancer

Small-cell lung cancer (SCLC) is the most aggressive form of lung cancer characterized by early metastasis and high mortality. In recent years, monotherapy and combination therapy of amrubicin with cisplatin or carboplatin has been actively studied and shown promise for the treatment of extensive di...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ding, Qian, Zhan, Jinbiao
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2013
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3738252/ https://www.ncbi.nlm.nih.gov/pubmed/23946645 http://dx.doi.org/10.2147/DDDT.S41910

Ejemplares similares

Efficacy and safety of amrubicin monotherapy after atezolizumab plus carboplatin and etoposide in patients with relapsed small-cell lung cancer
por: Imai, Hisao, et al.
Publicado: (2022)

Feasibility study of chemoradiotherapy followed by amrubicin and cisplatin for limited‐disease small cell lung cancer
por: Sekine, Ikuo, et al.
Publicado: (2016)

Comparison of carboplatin plus etoposide with amrubicin monotherapy for extensive‐disease small cell lung cancer in the elderly and patients with poor performance status
por: Igawa, Satoshi, et al.
Publicado: (2018)

Randomized phase III trial of amrubicin/cisplatin versus etoposide/cisplatin as first-line treatment for extensive small-cell lung cancer
por: Sun, Yan, et al.
Publicado: (2016)

Review of the Management of Relapsed Small-Cell Lung Cancer with Amrubicin Hydrochloride
por: Kimura, Tatsuo, et al.
Publicado: (2011)

Next-generation anthracycline for the management of small cell lung cancer: focus on amrubicin
por: Yamamoto, Michiko, et al.
Publicado: (2009)

Efficacy and safety of amrubicin hydrochloride for treatment of relapsed small cell lung cancer
por: Ogawara, Daiki, et al.
Publicado: (2010)

Comparison of Carboplatin With Cisplatin in Small Cell Lung Cancer in US Veterans
por: Azar, Ibrahim, et al.
Publicado: (2022)

Clinical significance of topoisomerase‐II expression in patients with advanced non‐small cell lung cancer treated with amrubicin
por: Sakurai, Reiko, et al.
Publicado: (2020)

Paclitaxel-etoposide-carboplatin/cisplatin versus etoposide-carboplatin/cisplatin as first-line treatment for combined small-cell lung cancer: a retrospective analysis of 62 cases
por: Li, Yue-Ya, et al.
Publicado: (2015)

Efficacy and safety of amrubicin therapy after chemoimmunotherapy in small cell lung cancer patients
por: Kushiro, Kohei, et al.
Publicado: (2022)

Picoplatin overcomes resistance to cell toxicity in small-cell lung cancer cells previously treated with cisplatin and carboplatin
por: Tang, Chi-Hui, et al.
Publicado: (2010)

Atezolizumab in combination with carboplatin and etoposide for heavily treated small cell lung cancer
por: Kataoka, Nobutaka, et al.
Publicado: (2020)

Pneumothorax triggered by the combination of gefitinib and amrubicin and treated with endobronchial silicone spigots
por: Imamura, Fumio, et al.
Publicado: (2015)

Risk of thromboembolism in cisplatin versus carboplatin-treated patients with lung cancer
por: Kim, Eric S., et al.
Publicado: (2017)

Incremental low doses of amrubicin for the treatment of bone marrow metastasis in small cell lung cancer
por: Asai, Nobuhiro, et al.
Publicado: (2013)

Evaluation of topotecan monotherapy for relapsed small-cell lung cancer after amrubicin monotherapy failure
por: Fujita, Kohei, et al.
Publicado: (2021)

Influencing factors of efficacy and long‐term use of amrubicin in patients with small cell lung cancer
por: Takahara, Yutaka, et al.
Publicado: (2023)

Cisplatin or carboplatin for advanced non-small cell lung cancer: does it really matter?
por: Kesireddy, Meghana, et al.
Publicado: (2021)

Correction: Risk of thromboembolism in cisplatin versus carboplatin-treated patients with lung cancer
Publicado: (2018)

Pemetrexed plus cisplatin/carboplatin in previously treated locally advanced or metastatic non-small cell lung cancer patients
por: Zhang, Guan-Zhong, et al.
Publicado: (2010)

Phase I study of amrubicin plus cisplatin and concurrent accelerated hyperfractionated thoracic radiotherapy for limited‐disease small cell lung cancer: protocol of ACIST study
por: Akagi, Kazumasa, et al.
Publicado: (2022)

Efficacy and Safety of Amrubicin in Small Cell Carcinoma Previously Treated with Immune Checkpoint Inhibitors and Chemotherapy
por: Nishimura, Tadashi, et al.
Publicado: (2022)

Amrubicin for relapsed small-cell lung cancer: a systematic review and meta-analysis of 803 patients
por: Horita, Nobuyuki, et al.
Publicado: (2016)

A retrospective study of amrubicin monotherapy for the treatment of relapsed small cell lung cancer in elderly patients
por: Imai, Hisao, et al.
Publicado: (2017)

Carboplatin versus cisplatin in combination with etoposide in the first-line treatment of small cell lung cancer: a pooled analysis
por: Jiang, Shiyu, et al.
Publicado: (2021)

Amrubicin monotherapy for elderly patients with relapsed extensive‐disease small‐cell lung cancer: A retrospective study
por: Sone, Hideyuki, et al.
Publicado: (2018)

Clinical impact of amrubicin monotherapy in patients with relapsed small cell lung cancer: a multicenter retrospective study
por: Uda, Sayaka, et al.
Publicado: (2022)

Potential Activity of Amrubicin as a Salvage Therapy for Merkel Cell Carcinoma
por: Sakaida, Emiko, et al.
Publicado: (2017)

The safety and efficacy of amrubicin in the treatment of previously untreated extensive-disease small-cell lung cancer: a meta-analysis
por: Wu, Ji-Feng, et al.
Publicado: (2019)

Effective Monotherapy with Amrubicin for a Refractory Extrapulmonary Small-Cell Carcinoma of the Liver
por: Isobe, Taichi, et al.
Publicado: (2009)

Carboplatin- and cisplatin-induced potentiation of moderate-dose radiation cytotoxicity in human lung cancer cell lines.
por: Groen, H. J., et al.
Publicado: (1995)

Long-term disease-free survivor of metastatic large-cell neuroendocrine carcinoma of the lung treated with amrubicin and irinotecan
por: Ryuge, Shinichiro, et al.
Publicado: (2009)

Phase III randomized trial comparing moderate-dose cisplatin to combined cisplatin and carboplatin in addition to mitomycin and ifosfamide in patients with stage IV non-small-cell lung cancer
por: Sculier, J-P, et al.
Publicado: (2000)

Impact of Amrubicin Monotherapy as Second-Line Chemotherapy on Outcomes in Elderly Patients with Relapsed Extensive-Disease Small-Cell Lung Cancer
por: Igawa, Satoshi, et al.
Publicado: (2020)

Efficacy of weekly amrubicin for refractory or relapsed non-small cell lung cancer: A protocol of systematic review and meta-analysis
por: Dang, Dong, et al.
Publicado: (2020)

Individual optimal dose of amrubicin to prevent severe neutropenia in Japanese patients with lung cancer
por: Makino, Yoshinori, et al.
Publicado: (2019)

Cisplatin/carboplatin cross-resistance in ovarian cancer.
por: Gore, M. E., et al.
Publicado: (1989)

Docetaxel-carboplatin in combination with erlotinib and/or bevacizumab in patients with non-small cell lung cancer
por: Boutsikou, Eftimia, et al.
Publicado: (2013)

Long-term Survival of a Patient with Small Cell Lung Cancer Secreting ADH and ACTH Simultaneously, Following the Prolonged Use of Amrubicin
por: Kosuda, Aya, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_vgllrmfcpua4jc2074brdmi8dh